ARCO · Musculoesquelético
ARCO 2019 revised ARCO staging of osteonecrosis of the femoral head
vigentePer-hip stage I-IV framework for nontraumatic osteonecrosis of the femoral head. A subchondral or necrotic-zone fracture is the decisive stage-II/III boundary; lesion size and location, symptoms, age and patient goals remain separate inputs and must not be inferred from the stage.
Índice de referência, não é suporte à decisão clínica. O RadCommons apresenta conteúdo de referência reescrito a partir de critérios publicados e com link para a fonte primária. Confira sempre a publicação primária vigente. Não é um dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.
Escala de categorias
As figuras e tabelas estão na fonte primária. Abrir a fonte. O RadCommons reescreve e cita, não reproduz figuras protegidas por direitos autorais.
Procedência e vigência
- Órgão emissor
- Association Research Circulation Osseous
- Versão
- 2019 revised staging; 2026 ARCO/AAOS care context
- Ano
- 2019
- Família
- léxico
- Tipo de lógica
- flat
- Modalidade
- MRI, XR, CT
- Fonte primária
- The 2019 Revised Version of Association Research Circulation Osseous Staging System of Osteonecrosis of the Femoral Head · doi:10.1016/j.arth.2019.11.029
- Última verificação
- 2026-07-24
- Última checagem
- 2026-08-12
Lógica de decisão
Forma estruturada (flat). Uma futura calculadora a lê; as categorias abaixo são a superfície legível.
Stage each hip from the highest directly supported structural finding. Fracture is the stage-II/III boundary; lesion size, location, symptoms and treatment choice remain explicit separate inputs.
Mostrar a lógica estruturada (JSON)
{
"categories": [
{
"outcome_code": "1",
"radiograph": "normal",
"MRI": "low_signal_band_on_T1_weighted_images",
"bone_scintigraphy": "positive_is_an_alternative_qualifier",
"subchondral_or_necrotic_zone_fracture": "absent",
"femoral_head_depression": "absent",
"osteoarthritis": "absent"
},
{
"outcome_code": "2",
"radiograph": "abnormal_sclerosis_focal_osteoporosis_or_cystic_change",
"subchondral_or_necrotic_zone_fracture": "absent",
"femoral_head_depression": "absent",
"osteoarthritis": "absent"
},
{
"outcome_code": "3",
"radiograph_or_CT": "subchondral_or_necrotic_zone_fracture",
"collapse": "may_be_present_or_absent",
"subdivisions": [
{
"code": "IIIA",
"femoral_head_depression": "less_than_or_equal_to_2_mm"
},
{
"code": "IIIB",
"femoral_head_depression": "greater_than_2_mm"
}
],
"osteoarthritis": "not_category_defining"
},
{
"outcome_code": "4",
"radiograph": "osteoarthritis_with_joint_space_narrowing_acetabular_change_and_or_joint_destruction",
"collapse": "usually_present"
}
],
"applicability": {
"intended_use": "Stage nontraumatic osteonecrosis of one femoral head using the 2019 revised ARCO system.",
"classification_unit": "one_hip_at_one_imaging_timepoint",
"bilateral_rule": "Stage the right and left hips independently and preserve laterality on every finding.",
"outside_scope": [
"traumatic_femoral_head_necrosis",
"other_skeletal_osteonecrosis_sites",
"lesion_size_or_location_classification",
"collapse_probability",
"symptom_grade",
"treatment_selection_by_stage_alone"
]
},
"imaging_gate": {
"MRI": "Preferred diagnostic test when radiographs are normal or suspicion remains; the canonical stage-I feature is a band-like low-signal lesion on T1-weighted images.",
"radiograph": "Required for the radiographic stage-II changes and stage-IV osteoarthritis descriptors but may miss an occult fracture.",
"CT": "CT or MRI is preferred to radiography for detecting a subchondral fracture. CT may show a fracture not evident on radiography or MRI and can move a hip from stage II to III.",
"scintigraphy": "A positive bone scan can support stage I in the 2019 definition, but current diagnostic guidance favors MRI.",
"adequacy_rule": "If fracture status is unresolved on available imaging, do not force stage II; return stage II versus III and identify CT or appropriate MRI review as the missing discriminator."
},
"staging_algorithm": [
{
"step": 1,
"if": "radiographic_osteoarthritis_with_joint_space_narrowing_acetabular_change_or_joint_destruction",
"output_code": "4"
},
{
"step": 2,
"if": "subchondral_or_necrotic_zone_fracture_on_radiograph_or_CT",
"output_code": "3",
"then": "measure_maximum_head_depression_to_assign_IIIA_or_IIIB"
},
{
"step": 3,
"if": "radiographic_sclerosis_focal_osteoporosis_or_cystic_change_without_fracture_flattening_or_osteoarthritis",
"output_code": "2"
},
{
"step": 4,
"if": "radiograph_normal_and_MRI_T1_low_signal_band_or_positive_bone_scan",
"output_code": "1"
},
{
"step": 5,
"if": "no_supported_osteonecrosis_or_key_imaging_missing",
"output": "not_classifiable_or_adjacent_stage_uncertainty"
}
],
"decisive_boundaries": {
"stage_1_2": "Any qualifying radiographic abnormality changes stage I to II; MRI lesion conspicuity or extent alone does not.",
"stage_2_3": "A subchondral or necrotic-zone fracture is stage III even before visible flattening. Do not require collapse to call stage III.",
"stage_3A_3B": "Measure maximal femoral-head depression against the expected contour: exactly 2 mm is IIIA; more than 2 mm is IIIB.",
"stage_3_4": "Collapse alone remains stage III. Stage IV requires secondary osteoarthritis such as joint-space loss, acetabular change or joint destruction.",
"worst_supported_feature": "Use the highest stage-defining feature in the same hip while retaining the modality and measurement that established it."
},
"revision_identity": {
"removed_stage_0": "The 2019 revision deleted historical stage 0. Do not emit 0 or map an all-imaging-negative hip to stage I.",
"stage_III_split": "The revision divides stage III at 2 mm of femoral-head depression into IIIA and IIIB.",
"separate_size_and_location": "The prior ARCO size/location subclassification was not incorporated into the revised stage. Lesion size, location and extent must be captured separately and must not change the I-IV code.",
"version_rule": "Return 2019 revised ARCO staging even though the primary article was published in 2020; the 2026 care guideline adds management context without changing the stage codes."
},
"required_separate_descriptors": {
"lesion_extent": "Report lesion size or percentage/volume only when measured with a named method; MRI can quantify extent and follow response.",
"lesion_location": "Report weight-bearing or lateral extension and any named JIC, modified Kerboul or other system separately; never translate it into an ARCO stage.",
"symptoms_and_function": "Record pain, functional limitation and symptom laterality independently.",
"patient_context": [
"age",
"etiology_and_risk_factors",
"duration",
"prior_treatment",
"contralateral_hip_status",
"comorbidity",
"patient_values"
]
},
"current_2026_care_context": {
"diagnosis": "MRI is recommended for diagnosis; CT or MRI may be used to identify a subchondral fracture, and MRI may quantify lesion area or extent.",
"asymptomatic_stage_I_or_II": "Intervention may be considered according to collapse risk, lesion size and extent, using low-morbidity options when appropriate; evidence is very low and the stage alone is insufficient.",
"symptomatic_stage_I_or_II": "Consider joint-preserving alternatives to total hip arthroplasty before fracture, with shared decision-making. Core decompression may be considered, and bone-marrow-cell augmentation may reduce collapse, but evidence does not establish one universally superior strategy.",
"selected_joint_preservation": "Vascularized fibular grafting or osteotomy may be considered for selected stage-I or II hips; recommendations are weak and patient selection matters.",
"stage_III": "Joint-preserving procedures have smaller and less predictable functional improvement than total hip arthroplasty after fracture/collapse, yet shared decision-making remains essential, especially for younger patients.",
"stage_IV": "Secondary osteoarthritis commonly leads to arthroplasty consideration, but candidacy still depends on symptoms, function, age, comorbidity and patient goals.",
"safety_rule": "Never generate decompression, grafting, osteotomy or arthroplasty as an automatic command from the ARCO stage. Integrate fracture, lesion size/location, symptoms, age, lifespan and patient preference."
},
"risk_and_interpretation": {
"ordinal_direction": "Later stage indicates structural progression from occult disease to radiographic change, fracture/collapse and secondary osteoarthritis.",
"no_per_stage_calibration": "The revised staging paper does not provide a calibrated individual collapse or arthroplasty probability for each code.",
"dominant_separate_predictors": "Lesion size and location are major determinants of collapse risk but are intentionally separate from the stage; a small stage-II lesion and a large stage-II lesion do not have identical risk.",
"serial_rule": "Store each hip's stage by examination date. A later higher stage must not overwrite the earlier baseline or imply the contralateral hip progressed."
},
"agent_output_contract": [
"right_and_left_hip_staged_separately",
"exact_ARCO_stage_and_IIIA_or_IIIB_substage_when_applicable",
"modality_and_finding_that_established_the_stage",
"fracture_status_and_CT_or_MRI_adequacy",
"maximum_head_depression_in_mm_for_stage_III",
"joint_space_acetabular_and_joint_destruction_findings",
"lesion_size_and_location_as_separate_named_descriptors",
"symptoms_age_etiology_prior_treatment_and_patient_goals",
"uncertainty_or_missing_discriminator_without_forced_stage",
"care_context_without_stage_only_treatment_command"
],
"supporting_sources": [
{
"role": "current_staging",
"citation": "Yoon et al. J Arthroplasty. 2020;35:933-940",
"doi": "10.1016/j.arth.2019.11.029",
"pmid": "31866252"
},
{
"role": "current_evidence_based_care_context",
"citation": "Cheng et al. JBJS Am. 2026;108:903-906",
"doi": "10.2106/JBJS.25.01616",
"pmid": "41961916"
}
],
"source_locator": "Yoon et al. 2019 revised ARCO staging paper, J Arthroplasty 2020, DOI 10.1016/j.arth.2019.11.029, abstract and staging table for stages I-IV, deletion of stage 0 and the 2 mm IIIA/IIIB split. ARCO/AAOS international evidence-based CPG 2026, DOI 10.2106/JBJS.25.01616, diagnostic imaging and stage-group treatment recommendations for the current care boundary."
}Categorias num relance
| Cat. | Significado | Conduta | Risco | Fonte |
|---|---|---|---|---|
| 1 | Grade 1 2019 revised ARCO stage I is a hip with normal radiographs but osteonecrosis demonstrated by a band-like low-signal lesion on T1-weighted MRI and/or a positive bone scan. There is no subchondral or necrotic-zone fracture, femoral-head depression or secondary osteoarthritis. Stage each hip independently and do not emit the deleted historical stage 0 for an imaging-negative hip. | MRI is the preferred diagnostic test. For an asymptomatic or symptomatic pre-fracture hip, discuss observation versus joint-preserving intervention using symptoms, lesion size and location, age and patient goals. The 2026 ARCO guideline allows consideration of core decompression and selected augmentation but does not establish one universally superior intervention or authorize a stage-I-only treatment command. | Stage I is structurally pre-fracture, but the stage supplies no calibrated individual probability of collapse. Lesion size and weight-bearing location are major separate determinants, so two stage-I hips can have materially different risk. Record the named size/location method, symptoms, etiology and serial imaging instead of assigning a stage-only percentage. | okfonte Yoon et al. J Arthroplasty 2020, DOI 10.1016/j.arth.2019.11.029, 2019 revised ARCO staging table and revision rationale; Cheng et al. JBJS 2026, DOI 10.2106/JBJS.25.01616, Recommendations on diagnostic MRI, asymptomatic stage I-II and core decompression; ARCO update review PMC8216992, 2019 staging and separate size/location systems. |
| 2 | Grade 2 2019 revised ARCO stage II has radiographic osteonecrosis such as sclerosis, focal osteoporosis or cystic change, but no subchondral or necrotic-zone fracture, no femoral-head flattening or depression and no secondary osteoarthritis. If fracture status is unresolved, especially on radiography alone, retain stage II versus III uncertainty and use CT or appropriate MRI review rather than assuming stage II. | For stage II without fracture, use shared decision-making informed by pain, function, lesion size and location, age, etiology and expected lifespan. Core decompression with or without bone-marrow-cell augmentation and selected vascularized grafting or osteotomy may be considered, but evidence is weak or low and does not support an automatic procedure. CT can be important when an occult fracture would change the stage and counseling. | Stage II remains pre-fracture but is not a uniform collapse-risk group. Extent and location are intentionally outside the 2019 stage and strongly modify risk; the stage paper provides no portable per-stage probability. A reported stage II should therefore include fracture-detection adequacy and a separate lesion-extent descriptor. | okfonte Yoon et al. 2020 primary revised staging table, stage II and deleted size/location subclasses; Cheng et al. 2026 guideline, diagnostic CT/MRI for subchondral fracture and stage I-II joint-preservation recommendations; PMC8216992, size/location as major collapse determinants distinct from ARCO stage. |
| 3 | Grade 3 2019 revised ARCO stage III requires a subchondral or necrotic-zone fracture on radiography or CT, with or without visible collapse. Measure maximum femoral-head depression: IIIA is 2 mm or less, including exactly 2 mm, and IIIB is more than 2 mm. A fracture is sufficient for stage III before flattening; collapse without secondary osteoarthritis remains stage III rather than IV. | After fracture or collapse, compare the smaller and less predictable functional benefit of joint preservation with total hip arthroplasty through shared decision-making, particularly in younger patients. Age, remaining lifespan, depression, lesion size/location, symptoms, function and preferences are required. Stage III does not autonomously select grafting, osteotomy or arthroplasty, and IIIA versus IIIB is not a stand-alone procedure rule. | Stage III demonstrates structural failure and generally carries greater progression and arthroplasty concern than pre-fracture stages, but neither IIIA nor IIIB has a universal individual outcome percentage in the staging system. Depression, extent, location, symptoms and patient factors remain necessary, and serial exams must preserve the date at which fracture or collapse first became visible. | okfonte Yoon et al. 2020 primary revised staging table, stage III fracture criterion and 2 mm IIIA/IIIB boundary; Cheng et al. 2026 guideline, stage-III joint-preservation versus total-hip-arthroplasty counseling and age, lesion-size and patient-value context. |
| 4 | Grade 4 2019 revised ARCO stage IV is secondary osteoarthritis on radiography, with joint-space narrowing, acetabular change and/or joint destruction after femoral-head osteonecrosis and collapse. Collapse alone is insufficient; verify an osteoarthritic joint or acetabular feature before moving a hip from stage III to IV. | Secondary osteoarthritis commonly makes total hip arthroplasty an important option, but management still depends on pain, disability, age, comorbidity, prior preservation procedures and patient goals. The stage must not be converted into an automatic arthroplasty order, and the contralateral hip requires its own independent stage and care plan. | Stage IV represents the most advanced structural category and established secondary joint degeneration, not a calibrated probability of pain, disability, surgical candidacy or implant outcome. Report function, symptoms, joint destruction, bone stock and patient context rather than treating the numeral as an individual prognosis. | okfonte Yoon et al. 2020 primary revised staging table, stage-IV joint-space, acetabular and joint-destruction criteria; Cheng et al. 2026 evidence-based guideline, treatment framework and shared-decision boundary for advanced nontraumatic osteonecrosis. |
Histórico de versões
| Data | Evento | Detalhe | Situação |
|---|---|---|---|
| 2026-07-25 | revised | Monitored source changed (content_hash). Detected automatically; awaiting reviewer confirmation. evidência | aguardando revisão |
| 2026-01-20 | revised | ARCO adopted an international evidence-based clinical practice guideline for nontraumatic femoral-head osteonecrosis. It supplies current imaging and care context without changing the 2019 stage codes. evidência | confirmado |
| 2019-12-24 | revised | ARCO published its 2019 revised staging: historical stage 0 was deleted, stage III was split at 2 mm of femoral-head depression, and prior size/location subclasses were left outside the I-IV stage. evidência | confirmado |
| 2019-06-01 | revised | ARCO classification revised (2019). | confirmado |
Quickstart da APIGET /api/v1/systems/arcoaberto
curl -s "https://radcommons.laudos.ai/api/v1/systems/arco"Ver documentação completa